Collegium Reports Record Fourth Quarter and Full-Year 2024 Financial Results
Portfolio Pulse from
Collegium Pharmaceutical reported record financial results for Q4 and full-year 2024, with net revenue of $181.9M for the quarter and $631.4M for the year. The company achieved a GAAP net income of $12.5M for the quarter and $69.2M for the year, and ended 2024 with $162.8M in cash and securities. They also repurchased $60M in shares and reaffirmed their 2025 guidance.
February 27, 2025 | 9:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Collegium Pharmaceutical reported record Q4 and full-year 2024 financial results, with significant net revenue and GAAP net income. The company also repurchased $60M in shares and reaffirmed 2025 guidance.
The record financial results, including high net revenue and GAAP net income, are positive indicators for Collegium Pharmaceutical. The share repurchase and reaffirmed guidance further support a positive outlook, likely boosting investor confidence and stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100